This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Lazar, H. L. Search for Related Content PubMed PubMed Citation Articles by Lazar, H. L. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Heart Surgery Related Collections CV surgery: other

(Circulation. 2004;110:II-274 – II-279.)
© 2004 American Heart Association, Inc.

Myocardial Protection and Vascular Biology

Soluble Human Complement Receptor 1 Limits Ischemic Damage in Cardiac Surgery Patients at High Risk Requiring Cardiopulmonary Bypass

Harold L. Lazar, MD; Paula M. Bokesch, MD; Frederick van Lenta, PhD; Carmel Fitzgerald, RN MS; Constance Emmett, MS; Henry C. Marsh, Jr, PhD; Una Ryan, PhD; OBE and the TP10 Cardiac Surgery Study Group

From Department of Cardiothoracic Surgery (H.L.L., C.F.), Boston University School of Medicine and Boston Medical Center, Boston, Mass; Department of Anesthesiology (P.M.B.), Emory University, Atlanta, Ga; Department of Laboratory Medicine (F.v.L.), Boston Medical Center, Boston, Mass; AVANT Immunotherapeutics, Inc (C.E., H.C.M., U.R.), Needham, Mass.

Correspondence to Harold L. Lazar, MD, Department of Cardiothoracic Surgery, Boston Medical Center, 88 East Newton Street, Boston, MA 02118. E-mail harold.lazar{at}bmc.org

Background— This study was undertaken to determine whether soluble human complement receptor type 1 (TP10), a potent inhibitor of complement activation, would reduce morbidity and mortality in high-risk patients undergoing cardiac surgery on cardiopulmonary bypass (CPB).

Methods— This was a randomized multicenter, prospective, placebo-controlled, double-blind study in which 564 high-risk patients undergoing cardiac surgery on CPB received an intravenous bolus of TP10 (1, 3, 5, 10 mg/kg) or placebo immediately before CPB. The primary endpoint was the composite events of death, myocardial infarction (MI), prolonged (24 hours) intra-aortic balloon pump support (IABP), and prolonged intubation.

Results— TP10 significantly inhibited complement activity after 10 to 15 minutes of CPB and this inhibition persisted for 3 days postoperatively. However, there was no difference in the primary endpoint between the 2 groups (33.7% placebo versus 31.4% TP10; P=0.31). The primary composite endpoint was, however, reduced in all male TP10 patients by 30% (P=0.025). TP10 reduced the incidence of death or MI in males by 36% (P=0.026), the incidence of death or MI in CABG males by 43% (P=0.043) and the need for prolonged IABP support in male CABG and valve patients by 100% (P=0.019). There was, however, no improvement seen in female TP10 patients. There were no significant differences in adverse events between the groups.

Conclusion— TP10 effectively inhibits complement activation during CPB; however, this was not associated with an improvement in the primary endpoint of the study. Nevertheless, TP10 did significantly decrease the incidence of mortality and MI in male patients.

Key Words: complement • cardiopulmonary bypass • myocardial ischemia